AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
AAC Accepts, published online ahead of print on 28 April 2008
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01596-07v1
52/7/2673    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Damle, B.
Right arrow Articles by Dowell, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Damle, B.
Right arrow Articles by Dowell, J.
Antimicrob. Agents Chemother. doi:10.1128/AAC.01596-07
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Pharmacokinetics and Tissue Distribution of Anidulafungin in Rats

Bharat Damle*, Martin Stogniew, and James Dowell

Pfizer Inc, New York, NY 10017; and Vicuron, a Subsidiary of Pfizer Inc, New York, New York

* To whom correspondence should be addressed. Email: bharat.damle{at}pfizer.com.


  Abstract

This study assessed the tissue distribution of anidulafungin in rats. Anidulafungin rapidly distributed into tissues, achieving peak concentrations within 30 minutes, and maintained levels above MICs for common pathogens over 72 h. In tissues susceptible to fungal infection (liver, lung, spleen, kidney), exposure was 9- to 12-fold higher than plasma.




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.